FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gert van Assche

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Anthony de Buck van Overstraeten; Freddy Penninckx; Paul Rutgeerts; Gert van Assche; Séverine Vermeire; Albert M Wolthuis; André D'Hoore
Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence.
Filip Baert; Philip Caenepeel; olivier dewit; Geert D'Haens; Dennis Franchimont; Elien Glorieus; Edouard Louis; Harald Peeters; Cathérine Reenaers; Gert van Assche
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Clémentine Perrier; Paul Rutgeerts; Frans Schuit; Dominiek Staelens; Gert van Assche; Séverine Vermeire; Isabelle Cleynen; Kris Covens; Gert De Hertogh; Marc Ferrante; Ingrid Arijs; Christine Breynaert; Jan L Ceuppens
Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gert van Assche (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anthony de Buck van Overstraeten; Freddy Penninckx; Paul Rutgeerts; Gert van Assche; Séverine Vermeire; Albert M Wolthuis; André D'Hoore
Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence.
Journal of Crohn's & colitis 2013;7(6):e227-31.
2013: Filip Baert; Philip Caenepeel; olivier dewit; Geert D'Haens; Dennis Franchimont; Elien Glorieus; Edouard Louis; Harald Peeters; Cathérine Reenaers; Gert van Assche
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Journal of Crohn's & colitis 2013;7(2):154-60.
2013: Clémentine Perrier; Paul Rutgeerts; Frans Schuit; Dominiek Staelens; Gert van Assche; Séverine Vermeire; Isabelle Cleynen; Kris Covens; Gert De Hertogh; Marc Ferrante; Ingrid Arijs; Christine Breynaert; Jan L Ceuppens
Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.
Immunology 2013;138(1):47-56.
2012: Axel Dignass; James O Lindsay; Gerassimos J Mantzaris; Gottfried Novacek; Tom Oresland; Walter Reinisch; Miquel Sans; Eduard Stange; Andreas Sturm; Simon Travis; Mathieu Allez; Jean-Frederic Colombel; Gert D'Haens; André D'Hoore; Severine Vermeire; Alastair Windsor; Gert van Assche
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.
Journal of Crohn's & colitis 2012;6(10):991-1030.
2012: Geert D'Haens; Marc Ferrante; Patricia Geens; Doreen Iwens; Liesbeth Moortgat; Maja Noman; Isolde Aerden; Filip Baert; Gert van Assche; Gust Van Olmen; Severine Vermeire; Paul Rutgeerts
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
Inflammatory bowel diseases 2012;18(12):2218-24.
2012: Talat Bessissow; Raf Bisschops; Marc Ferrante; Karel Geboes; Bart Lemmens; Paul Rutgeerts; Gert van Assche; Kristel Van Steen; Séverine Vermeire; Gert De Hertogh
Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing.
The American journal of gastroenterology 2012;107(11):1684-92.
2012: Marc Ferrante; Gert van Assche
Medical therapy and mucosal healing.
Current drug targets 2012;13(10):1294-9.
2012: Gert van Assche
The natural history of Crohn's disease: who holds the crystal ball?
Gut 2012;61(8):1106-7.
2012: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Classification of inflammatory bowel disease: the old and the new.
Current opinion in gastroenterology 2012;28(4):321-6.
2012: Paul Rutgeerts; William J Sandborn; Gert van Assche; Douglas C Wolf; Karel Geboes; Ashish Kumar; Andreas Lazar; Kathleen G Lomax; Paul F Pollack; Walter Reinisch; Anne Camez; Jean-Frédéric Colombel; Geert D'Haens
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Gastroenterology 2012;142(5):1102-1111.e2.
2012: Gert van Assche; L Van der Biest; Severine Vermeire; A Wolthuis; Marc Ferrante; M Noman; Freddy Penninckx; K Rans; Paul Rutgeerts; Andre D'Hoore
Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo-controlled crossover study.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2012;14(4):e181-6.
2012: Marc Ferrante; Konstantinos Karmiris; Peter L Lakatos; Evan Newnham; Jean-Frédéric Colombel; Julian Panés; Walter Reinisch; Jesse Siffledeen; Andreas Sturm; Simon Travis; Gert van Assche; C Janneke van der Woude; Zuzana Zelinkova; Remo Panaccione
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
Journal of Crohn's & colitis 2012;6(1):116-31.
2012: Marko Brinar; Isabelle Cleynen; Karel Geboes; Liesbet Henckaerts; Bart Lemmens; Paul Rutgeerts; Xavier Sagaert; Gert van Assche; Séverine Vermeire; Gert De Hertogh
Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients.
Journal of Crohn's & colitis 2012;6(1):43-50.
2011: Gert van Assche; James D Lewis; Gary R Lichtenstein; Edward V Loftus; Qin Ouyang; Julian Panes; William J Sandborn; Corey A Siegel; Simon P L Travis; Jean-Frederic Colombel
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
The American journal of gastroenterology 2011;106(9):1594-602; quiz 1593, 1603.
2011: Fabian Schnitzler; Bernard Spitz; Gert van Assche; Kristel van Steen; Séverine Vermeire; Vera Ballet; Marc Ferrante; Herma Fidder; Ilse Hoffman; Maja Noman; Paul Rutgeerts
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Inflammatory bowel diseases 2011;17(9):1846-54.
2011: Christine Breynaert; Marc Ferrante; Herma Fidder; Kristel van Steen; Maja Noman; Vera Ballet; Séverine Vermeire; Paul Rutgeerts; Gert van Assche
Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
The American journal of gastroenterology 2011;106(4):778-85.
2011: Ingrid Arijs; Gert De Hertogh; Kathleen Machiels; Kristel van Steen; Katleen Lemaire; Anica Schraenen; Leentje Van Lommel; Roel Quintens; Gert van Assche; Séverine Vermeire; Frans Schuit; Paul Rutgeerts
Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.
The American journal of gastroenterology 2011;106(4):748-61.
2011: Gert van Assche
Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
Gut 2011;60(3):285-6.
2011: Konstantinos Karmiris; Didier Bielen; Dirk Vanbeckevoort; Severine Vermeire; Georges Coremans; Paul Rutgeerts; Gert van Assche
Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(2):130-6.
2011: Séverine Vermeire; Gert van Assche; Paul Rutgeerts
Inflammatory bowel disease and colitis: new concepts from the bench and the clinic.
Current opinion in gastroenterology 2011;27(1):32-7.
2011: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
Management of acute severe ulcerative colitis.
Gut 2011;60(1):130-3.
2010: Ingrid Arijs; Roel Quintens; Leentje Van Lommel; Kristel van Steen; Gert De Hertogh; Katleen Lemaire; Anica Schraenen; Clémentine Perrier; Gert van Assche; Séverine Vermeire; Karel Geboes; Frans Schuit; Paul Rutgeerts
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Inflammatory bowel diseases 2010;16(12):2090-8.
2010: Marko Brinar; Isabelle Cleynen; Tamara Coopmans; Gert van Assche; Paul Rutgeerts; Severine Vermeire
Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity.
Gut 2010;59(12):1728-9; author reply 1729-30.
2010: I J J Claes; Sarah Lebeer; Chong Shen; Tine L A Verhoeven; E Dilissen; Gert De Hertogh; dominique ma bullens; Jan L Ceuppens; Gert van Assche; Severine Vermeire; Paul Rutgeerts; Jos Vanderleyden; Sigrid C J De Keersmaecker
Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis.
Clinical and experimental immunology 2010;162(2):306-14.
2010: Matthieu Allez; Konstantinos Karmiris; Edouard Louis; Gert van Assche; Shomron Ben-Horin; Amir Klein; Janneke Van der Woude; Filip Baert; Rami Eliakim; Konstantinos Katsanos; Jørn Brynskov; Flavio Steinwurz; Silvio Danese; Severine Vermeire; Jean-Luc Teillaud; Marc Lémann; Yehuda Chowers
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
Journal of Crohn's & colitis 2010;4(4):355-66.
2010: Gert van Assche; Séverine Vermeire; Maja Noman; Christine Amant; Ellen Weyts; Anita Vleminckx; Marie-Josée Vermeyen; Paul Rutgeerts
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Journal of Crohn's & colitis 2010;4(3):329-33.
2010: Zhe Li; Ingrid Arijs; Gert De Hertogh; Severine Vermeire; Maja Noman; dominique ma bullens; Lieve Coorevits; Xavier Sagaert; Frans Schuit; Paul Rutgeerts; Jan L Ceuppens; Gert van Assche
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Inflammatory bowel diseases 2010;16(8):1299-310.
2010: Peter Suenaert; Philippe Maerten; Gert van Assche; Willy Van Driessche; Karel Geboes; Veerle Bulteel; Jeannine Simaels; Patrick Augustijns; Jan L Ceuppens; Paul Rutgeerts; Clémentine Perrier
Effects of T cell-induced colonic inflammation on epithelial barrier function.
Inflammatory bowel diseases 2010;16(8):1322-31.
2010: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Role of genetics in prediction of disease course and response to therapy.
World journal of gastroenterology : WJG 2010;16(21):2609-15.
2010: C Thienpont; A D'Hoore; Severine Vermeire; I Demedts; Raf Bisschops; Georges Coremans; Paul Rutgeerts; Gert van Assche
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy.
Gut 2010;59(3):320-4.
2010: Gert van Assche; Axel Dignass; Julian Panes; Laurent Beaugerie; John Karagiannis; Mathieu Allez; Thomas Ochsenkühn; Tim Orchard; Gerhard Rogler; Edouard Louis; Limas Kupcinskas; Gerassimos Mantzaris; Simon Travis; Eduard Stange
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.
Journal of Crohn's & colitis 2010;4(1):7-27.
2010: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
Mucosal healing and anti TNFs in IBD.
Current drug targets 2010;11(2):227-33.
2010: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
The potential for disease modification in Crohn's disease.
Nature reviews. Gastroenterology & hepatology 2010;7(2):79-85.
2010: Filip Baert; Liesbeth Moortgat; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Martine De Vos; Pieter Stokkers; Daniel Hommes; Paul Rutgeerts; Severine Vermeire; Geert D'Haens
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Gastroenterology 2010;138(2):463-8; quiz e10-1.
2010: Marc Ferrante; Geert D'Haens; olivier dewit; Filip Baert; Jan Holvoet; Karel Geboes; Gert De Hertogh; Gert van Assche; Severine Vermeire; Paul Rutgeerts
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series.
Inflammatory bowel diseases 2010;16(2):243-9.
2010: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Vaccination and infection prevention in inflammatory bowel disease.
F1000 medicine reports 2010;2():80.
2010: Paul Rutgeerts; Severine Vermeire; Gert van Assche
Predicting the response to infliximab from trough serum levels.
Gut 2010;59(1):7-8.
2009: Marc Ferrante; Geert D'Haens; Paul Rutgeerts; Séverine Vermeire; Gert van Assche
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Current gastroenterology reports 2009;11(6):504-8.
2009: I Arijs; K Li; G Toedter; R Quintens; L Van Lommel; Kristel van Steen; P Leemans; Gert De Hertogh; K Lemaire; Marc Ferrante; F Schnitzler; Lieven Thorrez; K Ma; X-Y R Song; C Marano; Gert van Assche; Severine Vermeire; Karel Geboes; F Schuit; F Baribaud; Paul Rutgeerts
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
Gut 2009;58(12):1612-9.
2009: Konstantinos Karmiris; Gilles Paintaud; Maja Noman; Charlotte Magdelaine-Beuzelin; Marc Ferrante; Danielle Degenne; Kathleen Claes; Tamara Coopman; Nele Van Schuerbeek; Gert van Assche; Severine Vermeire; Paul Rutgeerts
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Gastroenterology 2009;137(5):1628-40.
2009: Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert van Assche; Ilse Hoffman; Kristel van Steen; Severine Vermeire; Paul Rutgeerts
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Inflammatory bowel diseases 2009;15(9):1295-301.
2009: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Current opinion in gastroenterology 2009;25(4):323-8.
2009: Marc Ferrante; Andre D'Hoore; Severine Vermeire; S Declerck; Maja Noman; Gert van Assche; Ilse Hoffman; Paul Rutgeerts; Freddy Penninckx
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis.
Inflammatory bowel diseases 2009;15(7):1062-70.
2009: Mirjam Bueno de Mesquita; Marc Ferrante; Liesbet Henckaerts; Marie Joossens; Virginie Janssens; Tibor Hlavaty; Marie Pierik; Sofie Joossens; Nele Van Schuerbeek; Gert van Assche; Paul Rutgeerts; Severine Vermeire; Ilse Hoffman
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease.
European journal of pediatrics 2009;168(5):575-83.
2009: Paul Rutgeerts; Severine Vermeire; Gert van Assche
Biological therapies for inflammatory bowel diseases.
Gastroenterology 2009;136(4):1182-97.
2009: H Fidder; F Schnitzler; Marc Ferrante; Maja Noman; K Katsanos; Siegfried Segaert; Liesbet Henckaerts; Gert van Assche; Severine Vermeire; Paul Rutgeerts
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Gut 2009;58(4):501-8.
2009: F Schnitzler; H Fidder; Marc Ferrante; Maja Noman; I Arijs; Gert van Assche; Ilse Hoffman; Kristel van Steen; Severine Vermeire; Paul Rutgeerts
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Gut 2009;58(4):492-500.
2009: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Genetic analysis to predict prognosis at the onset of Crohn's disease: not yet ready for prime time?
Gut 2009;58(3):323-4.
2009: Marc Ferrante; Séverine Vermeire; Gert van Assche; Paul Rutgeerts
Reply to Dr. Caprilli et al.'s letter.
Journal of Crohn's & colitis 2009;3(1):45.
2009: Peter Bossuyt; Jan Verhaegen; Gert van Assche; Paul Rutgeerts; Séverine Vermeire
Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease.
Journal of Crohn's & colitis 2009;3(1):4-7.
2009: Ingrid Arijs; Gert De Hertogh; Katleen Lemaire; Roel Quintens; Leentje Van Lommel; Kristel van Steen; Peter Leemans; Isabelle Cleynen; Gert van Assche; Severine Vermeire; Karel Geboes; Frans Schuit; Paul Rutgeerts
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.
PloS one 2009;4(11):e7984.
2008: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
Management of loss of response to anti-TNF drugs: Change the dose or change the drug?
Journal of Crohn's & colitis 2008;2(4):348-51.
2008: C Breynaert; Severine Vermeire; Paul Rutgeerts; Gert van Assche
Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?
Acta gastro-enterologica Belgica 2008;71(4):367-72.
2008: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
What can we expect from endoscopic dilation of the stenotic tract in Crohn's disease?
Inflammatory bowel diseases 2008;14 Suppl 2():S275-6.
2008: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Should family members of IBD patients be screened for CARD15/NOD2 mutations?
Inflammatory bowel diseases 2008;14 Suppl 2():S190-1.
2008: Paul Rutgeerts; Severine Vermeire; Gert van Assche
What is the role of endoscopy in predicting Crohn's disease relapse or course?
Inflammatory bowel diseases 2008;14 Suppl 2():S183-4.
2008: Paul Rutgeerts; Gert van Assche
What is the role of endoscopy in the postoperative management of Crohn's disease?
Inflammatory bowel diseases 2008;14 Suppl 2():S179-80.
2008: Geert D'Haens; Severine Vermeire; Gert van Assche; Maja Noman; Isolde Aerden; Gust Van Olmen; Paul Rutgeerts
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.
Gastroenterology 2008;135(4):1123-9.
2008: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Treatment of severe steroid refractory ulcerative colitis.
World journal of gastroenterology : WJG 2008;14(36):5508-11.
2008: Marc Ferrante; Séverine Vermeire; Herma Fidder; Fabian Schnitzler; Maja Noman; Gert van Assche; Gert De Hertogh; Ilse Hoffman; Andre D'Hoore; Kristel van Steen; Karel Geboes; Freddy Penninckx; Paul Rutgeerts
Long-term outcome after infliximab for refractory ulcerative colitis.
Journal of Crohn's & colitis 2008;2(3):219-25.
2008: John Burke; Marc Ferrante; Karen Dejaegher; R William G Watson; Neil Docherty; Gert De Hertogh; Severine Vermeire; Paul Rutgeerts; Andre D'Hoore; Freddy Penninckx; Karel Geboes; Gert van Assche; Ronan O'Connell
Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease.
Inflammatory bowel diseases 2008;14(9):1197-204.
2008: I Hoffman; Severine Vermeire; Gert van Assche; Paul Rutgeerts
Infliximab for pediatric Crohn's disease.
Drugs of today (Barcelona, Spain : 1998) 2008;44(8):615-28.
2008: Marc Ferrante; Sarah Declerck; Tamara Coopmans; Gert De Hertogh; Gert van Assche; Freddy Penninckx; Paul Rutgeerts; Karel Geboes; Andre D'Hoore; Séverine Vermeire
Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes.
Journal of Crohn's & colitis 2008;2(2):142-51.
2008: Severine Vermeire; Nathalie Vermeulen; Gert van Assche; Xavier Bossuyt; Paul Rutgeerts
(Auto)antibodies in inflammatory bowel diseases.
Gastroenterology clinics of North America 2008;37(2):429-38, vii.
2008: Gert van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Severine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Gastroenterology 2008;134(7):1861-8.
2008: Gert van Assche
Does mucosal healing impact patient outcomes long-term?
Inflammatory bowel diseases 2008;14(4):577-8.
2008: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van de Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Lancet 2008;371(9613):660-7.
2008: Gert van Assche; Séverine Vermeire; Paul Rutgeerts
Infliximab: the evidence for its place in therapy in ulcerative colitis.
Core evidence 2008;2(3):151-61.
2008: Gert van Assche
Optimizing the benefit to risk ratio of medical therapy of inflammatory bowel diseases.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 2008;70(5-6):339-46.
2008: Marc Ferrante; Sarah Declerck; Gert De Hertogh; Gert van Assche; Karel Geboes; Paul Rutgeerts; Freddy Penninckx; Severine Vermeire; Andre D'Hoore
Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Inflammatory bowel diseases 2008;14(1):20-8.
2007: Konstantinos Katsanos; Etienne Cavalier; Marc Ferrante; Valérie Van Hauwaert; Liesbet Henckaerts; Fabian Schnitzler; Afroditi Katsaraki; Maja Noman; Séverine Vermeire; Epameinondas V Tsianos; Paul Rutgeerts; Jean-Paul Chapelle; Gert van Assche
Intravenous iron therapy restores functional iron deficiency induced by infliximab.
Journal of Crohn's & colitis 2007;1(2):97-105.
2007: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Adalimumab in Crohn's disease.
Biologics : targets & therapy 2007;1(4):355-65.
2007: Marc Ferrante; Liesbet Henckaerts; Marie Joossens; Marie Pierik; Sofie Joossens; Nir Dotan; Gary L Norman; Rom Altstock; Kristel van Steen; Paul Rutgeerts; Gert van Assche; Severine Vermeire
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.
Gut 2007;56(10):1394-403.
2007: Severine Vermeire; Maja Noman; Gert van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Gut 2007;56(9):1226-31.
2007: Paul Rutgeerts; Severine Vermeire; Gert van Assche
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Gut 2007;56(4):453-5.
2007: Gert van Assche
Emerging drugs to treat Crohn's disease.
Expert opinion on emerging drugs 2007;12(1):49-59.
2007: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Endoscopic therapy of strictures in Crohn's disease.
Inflammatory bowel diseases 2007;13(3):356-8; discussion 362-3.
2007: Chong Shen; Gert De Hertogh; dominique ma bullens; Gert van Assche; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens
Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?
Inflammatory bowel diseases 2007;13(3):308-16.
2007: Marc Ferrante; Severine Vermeire; Konstantinos Katsanos; Maja Noman; Gert van Assche; Fabian Schnitzler; Ingrid Arijs; Gert De Hertogh; Ilse Hoffman; J Karel Geboes; Paul Rutgeerts
Predictors of early response to infliximab in patients with ulcerative colitis.
Inflammatory bowel diseases 2007;13(2):123-8.
2006: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Gastroenterology clinics of North America 2006;35(4):743-56.
2006: Gert van Assche; William J Sandborn; Brian G Feagan; Bruce A Salzberg; D Silvers; P S Monroe; W M Pandak; F H Anderson; John Valentine; G E Wild; D J Geenen; R Sprague; S R Targan; Paul Rutgeerts; V Vexler; D Young; R S Shames
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Gut 2006;55(11):1568-74.
2006: Marc Ferrante; Freddy Penninckx; Gert De Hertogh; Karel Geboes; Andre D'Hoore; Maja Noman; Severine Vermeire; Paul Rutgeerts; Gert van Assche
Protein-losing enteropathy in Crohn's disease.
Acta gastro-enterologica Belgica 2006;69(4):384-9.
2006: Marc Ferrante; Marie Pierik; Liesbet Henckaerts; Marie Joossens; Karolien Claes; Nele Van Schuerbeek; Robert Francois Vlietinck; Paul Rutgeerts; Gert van Assche; Severine Vermeire
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease.
Inflammatory bowel diseases 2006;12(9):870-8.
2006: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Safety issues with biological therapies for inflammatory bowel disease.
Current opinion in gastroenterology 2006;22(4):370-6.
2006: David N Moskovitz; Gert van Assche; Benedikte Maenhout; Joris Arts; Marc Ferrante; Severine Vermeire; Paul Rutgeerts
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(6):760-5.
2006: Marc Ferrante; Gert De Hertogh; Tibor Hlavaty; Geert D'Haens; Freddy Penninckx; Andre D'Hoore; Severine Vermeire; Paul Rutgeerts; Karel Geboes; Gert van Assche
The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence.
Gastroenterology 2006;130(6):1595-606.
2006: P Stas; Andre D'Hoore; Gert van Assche; Karel Geboes; E Steenkiste; Freddy Penninckx; Paul Rutgeerts; Severine Vermeire
Miliary tuberculosis following infliximab therapy for Crohn disease: A case report and review of the literature.
Acta gastro-enterologica Belgica 2006;69(2):217-20.
2006: Tibor Hlavaty; Philippe Persoons; Severine Vermeire; Marc Ferrante; Marie Pierik; Gert van Assche; Paul Rutgeerts
Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease.
Inflammatory bowel diseases 2006;12(3):199-204.
2006: Severine Vermeire; Gert van Assche; Paul Rutgeerts
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Gut 2006;55(3):426-31.
2006: Paul Rutgeerts; Gert van Assche; Severine Vermeire
Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Alimentary pharmacology & therapeutics 2006;23(4):451-63.
2006: Philippe Maerten; B S Kwon; Chong Shen; Gert De Hertogh; Pascal Cadot; dominique ma bullens; Lut Overbergh; Chantal Mathieu; Gert van Assche; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens
Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.
Clinical and experimental immunology 2006;143(2):228-36.
2006: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Emerging biological treatments in inflammatory bowel diseases.
Digestive diseases (Basel, Switzerland) 2006;24(1-2):131-6.
2006: Chong Shen; Gert van Assche; Paul Rutgeerts; Jan L Ceuppens
Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model.
Inflammatory bowel diseases 2006;12(1):22-8.
2005: Severine Vermeire; Gert van Assche; Paul Rutgeerts
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases.
Nature clinical practice. Gastroenterology & hepatology 2005;2(12):580-6.
2005: Philippe Maerten; Chong Shen; dominique ma bullens; Gert van Assche; Stefaan W Van Gool; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens
Effects of interleukin 4 on CD25+CD4+ regulatory T cell function.
Journal of autoimmunity 2005;25(2):112-20.
2005: Gert van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Severine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
The New England journal of medicine 2005;353(4):362-8.
2005: Philippe Persoons; Severine Vermeire; Koen Demyttenaere; Benjamin Fischler; Joris Vandenberghe; Lukas Van Oudenhove; Marie Pierik; Tibor Hlavaty; Gert van Assche; Maja Noman; Paul Rutgeerts
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Alimentary pharmacology & therapeutics 2005;22(2):101-10.
2005: Gert van Assche
Is endoscopic balloon therapy an effective treatment for patients with Crohn's disease strictures?
Nature clinical practice. Gastroenterology & hepatology 2005;2(7):298-9.
2005: Peter Suenaert; Veerle Bulteel; Severine Vermeire; Maja Noman; Gert van Assche; Paul Rutgeerts
Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent.
Inflammatory bowel diseases 2005;11(7):667-73.
2005: Gert van Assche; Severine Vermeire; Paul Rutgeerts
Medical treatment of inflammatory bowel diseases.
Current opinion in gastroenterology 2005;21(4):443-7.
2005: Marc Ferrante; Gert De Hertogh; Freddy Penninckx; Gert van Assche
Protein-losing enteropathy in Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005;3(6):A25.
2005: Chong Shen; Philippe Maerten; Karel Geboes; Gert van Assche; Paul Rutgeerts; Jan L Ceuppens
Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model.
Clinical immunology (Orlando, Fla.) 2005;115(3):250-9.
2005: Paul Rutgeerts; Gert van Assche; Severine Vermeire; Geert D'Haens; Filip Baert; Maja Noman; Isolde Aerden; Gert De Hertogh; Karel Geboes; Martin Hiele; Andre D'Hoore; Freddy Penninckx
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.
Gastroenterology 2005;128(4):856-61.
2005: Marie Pierik; Gert De Hertogh; Severine Vermeire; Gert van Assche; Peter Van Eyken; Sofie Joossens; Greet Claessens; Robert Francois Vlietinck; Paul Rutgeerts; Karel Geboes
Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's disease.
Gut 2005;54(2):223-7.
2004: Marco Daperno; Geert D'Haens; Gert van Assche; Filip Baert; Philippe Bulois; Vincent Maunoury; Raffaello Sostegni; Rodolfo Rocca; Angelo Pera; Annemie Gevers; Jean-Yves Mary; Jean-Frédéric Colombel; Paul Rutgeerts
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
Gastrointestinal endoscopy 2004;60(4):505-12.
2004: Filip Baert; Severine Vermeire; Maja Noman; Gert van Assche; Geert D'Haens; Paul Rutgeerts
Management of ulcerative colitis and Crohn's disease.
Acta clinica Belgica 2004;59(5):304-14.
2004: Severine Vermeire; Gert van Assche; Paul Rutgeerts
C-reactive protein as a marker for inflammatory bowel disease.
Inflammatory bowel diseases 2004;10(5):661-5.
2004: Philippe Maerten; Karel Geboes; Gert De Hertogh; Chong Shen; Pascal Cadot; dominique ma bullens; Gert van Assche; Freddy Penninckx; Paul Rutgeerts; Jan L Ceuppens
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease.
Clinical immunology (Orlando, Fla.) 2004;112(3):239-46.
2004: Klara Gijsbers; Gert van Assche; Sofie Joossens; Sofie Struyf; Paul Proost; Paul Rutgeerts; Karel Geboes; Jo Van Damme
CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue.
European journal of immunology 2004;34(7):1992-2000.
2004: Chong Shen; dominique ma bullens; Ahmad Kasran; Philippe Maerten; Louis Boon; johannes aerts; Gert van Assche; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
International immunopharmacology 2004;4(7):939-51.
2004: Gert van Assche; Paul Rutgeerts
Medical management of postoperative recurrence in Crohn's disease.
Gastroenterology clinics of North America 2004;33(2):347-60, x.
2004: Paul Rutgeerts; Gert van Assche; Severine Vermeire
Optimizing anti-TNF treatment in inflammatory bowel disease.
Gastroenterology 2004;126(6):1593-610.
2004: L Marchal; Geert D'Haens; Gert van Assche; Severine Vermeire; Maja Noman; Marc Ferrante; Martin Hiele; M Bueno De Mesquita; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Alimentary pharmacology & therapeutics 2004;19(7):749-54.
2004: Joris Arts; Geert D'Haens; Miranda Zeegers; Gert van Assche; Martin Hiele; Andre D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.
Inflammatory bowel diseases 2004;10(2):73-8.
2004: Philippe Maerten; Chong Shen; Stefaan Colpaert; Zhanju Liu; dominique ma bullens; Gert van Assche; Freddy Penninckx; Karel Geboes; G Vanham; Paul Rutgeerts; Jan L Ceuppens
Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models.
Clinical and experimental immunology 2004;135(2):310-7.
2004: Gert van Assche; Karel Geboes; Paul Rutgeerts
Medical therapy for Crohn's disease strictures.
Inflammatory bowel diseases 2004;10(1):55-60.
2003: Gert van Assche; Geert D'Haens; Maja Noman; Severine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.
Gastroenterology 2003;125(4):1025-31.
2003: Severine Vermeire; Maja Noman; Gert van Assche; Filip Baert; Kristel van Steen; Nele Esters; Sofie Joossens; Xavier Bossuyt; Paul Rutgeerts
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Gastroenterology 2003;125(1):32-9.
2003: Filip Baert; Maja Noman; Severine Vermeire; Gert van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
The New England journal of medicine 2003;348(7):601-8.
2003: Gert van Assche; Ignace Dalle; Maja Noman; Isolde Aerden; Caroline Swijsen; Katrien Asnong; Bart Maes; Jan L Ceuppens; Karel Geboes; Paul Rutgeerts
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.
The American journal of gastroenterology 2003;98(2):369-76.
2003: Gert van Assche; Dirk Vanbeckevoort; Didier Bielen; Georges Coremans; Isolde Aerden; Maja Noman; Andre D'Hoore; Freddy Penninckx; Guy Marchal; Freddy Cornillie; Paul Rutgeerts
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
The American journal of gastroenterology 2003;98(2):332-9.
2003: Paul Rutgeerts; Liesbeth Lemmens; Gert van Assche; Maja Noman; I Borghini-Fuhrer; Rene Goedkoop
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study.
Alimentary pharmacology & therapeutics 2003;17(2):185-92.
2002: Gert van Assche; Filip Baert; Marc De Reuck; Martine De Vos; Olivier De Wit; Pierre Hoang; Edouard Louis; Fazia Mana; Paul A Pelckmans; Paul Rutgeerts; André Van Gossum; Geert D'Haens
The role of aminosalicylates in the treatment of ulcerative colitis.
Acta gastro-enterologica Belgica 2002;65(4):196-9.
2002: Severine Vermeire; Edouard Louis; An Carbonez; Gert van Assche; Maja Noman; Jacques Belaiche; Martine De Vos; André Van Gossum; Paul Pescatore; René Fiasse; Paul A Pelckmans; Hendrik Reynaert; Geert D'Haens; Paul Rutgeerts
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
The American journal of gastroenterology 2002;97(9):2357-63.
2002: Peter Suenaert; Veerle Bulteel; Liesbeth Lemmens; Maja Noman; benny geypens; Gert van Assche; Karel Geboes; Jan L Ceuppens; Paul Rutgeerts
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
The American journal of gastroenterology 2002;97(8):2000-4.
2002: Gert van Assche; Paul Rutgeerts
Antiadhesion molecule therapy in inflammatory bowel disease.
Inflammatory bowel diseases 2002;8(4):291-300.
2001: Freddy Cornillie; D Shealy; Geert D'Haens; Karel Geboes; Gert van Assche; J Ceuppens; C Wagner; TF Schaible; Scott Plevy; Stephan R Targan; Paul Rutgeerts
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Alimentary pharmacology & therapeutics 2001;15(4):463-73.
2001: Leen Thielemans; Inge Depoortere; Gert van Assche; E Bender; Theo L Peeters
Demonstration of a functional motilin receptor in TE671 cells from human cerebellum.
Brain research 2001;895(1-2):119-28.
2001: Inge Depoortere; Theo Thijs; Leen Thielemans; James Carl Keith; Gert van Assche; Theo L Peeters
Effect of recombinant human interleukin-11 on motilin and substance P release in normal and inflamed rabbits.
Regulatory peptides 2001;97(2-3):111-9.
2001: Inge Depoortere; Gert van Assche; Theo L Peeters
Motilin receptor density in inflamed and noninflamed tissue in rabbit TNBS-induced colitis.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2001;13(1):55-63.
2001: Gert van Assche; Inge Depoortere; Theo Thijs; Ludwig Missiaen; F Penninckx; H Takanashi; Karel Geboes; Jozef Janssens; Theo L Peeters
Contractile effects and intracellular Ca2+ signalling induced by motilin and erythromycin in the circular smooth muscle of human colon.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2001;13(1):27-35.
2000: Inge Depoortere; Theo Thijs; Gert van Assche; James Carl Keith; Theo L Peeters
Dose-dependent effects of recombinant human interleukin-11 on contractile properties in rabbit 2,4,6-trinitrobenzene sulfonic acid colitis.
The Journal of pharmacology and experimental therapeutics 2000;294(3):983-90.
1999: Inge Depoortere; Gert van Assche; Theo Thijs; Karel Geboes; Theo L Peeters
Differential changes in ACh-, motilin-, substance P-, and K(+)-induced contractility in rabbit colitis.
The American journal of physiology 1999;277(1 Pt 1):G61-8.
1999: Gert van Assche; Inge Depoortere; R de Vos; K Geboes; JJ Janssens; S M Collins; Theo L Peeters
Region-specific antiproliferative effect of VIP and PACAP-(1-38) on rabbit enteric smooth muscle.
The American journal of physiology 1999;276(1 Pt 1):G303-10.
1998: Gert van Assche; Inge Depoortere; Theo L Peeters
Localization of motilin binding sites in subcellular fractions from rabbit antral and colonic smooth muscle tissue.
Regulatory peptides 1998;77(1-3):89-94.
1997: Inge Depoortere; Gert van Assche; Theo L Peeters
Distribution and subcellular localization of motilin binding sites in the rabbit brain.
Brain research 1997;777(1-2):103-9.
1997: Gert van Assche; Inge Depoortere; Theo Thijs; JJ Janssens; Theo L Peeters
Concentration-dependent stimulation of cholinergic motor nerves or smooth muscle by [Nle13]motilin in the isolated rabbit gastric antrum.
European journal of pharmacology 1997;337(2-3):267-74.
1995: P De Clercq; A Vandermeers; Gert van Assche; R Fiasse; Inge Depoortere; MC Vandermeers-Piret; P Deprez; Theo L Peeters
Purification and amino acid sequence of human motilin isolated from a motilin containing liver metastasis.
Regulatory peptides 1995;55(1):79-84.